
| Supplementary Table 1 | . The score standards of | f osteoarthritic damage |
|-----------------------|--------------------------|-------------------------|
|-----------------------|--------------------------|-------------------------|

| Grade | Osteoarthritic damage |
|-------|---|
| 0 | Normal |
| 0.5 | Loss of Safranin-O without structural changes |
| 1 | Small fibrillations without loss of cartilage |
| 2 | Vertical clefts down to the layer immediately below the superficial layer and some loss of surface lamina |
| 3 | Verical clefts/erosion to the calcified cartilage extending to <25% of the articular surface |
| 4 | Vertical clefts/erosion to the calcified cartilage extending to 25-50% of the articular surface |
| 5 | Vertical clefts/erosion to the calcified cartilage extending to 50-75% of the articular surface |
| • | |

6 Vertical clefts/erosion to the calcified cartilage extending >75% of the articular surface



Supplementary Figure 1. ZG slows cartilage degeneration in DMM mice at 4th week. A. Joint histology in the DMM model. Knee joint tissue sections were from DMM mice following 4 weeks of treatment (ZG) and normal saline treatment (NS). Joint sections were stained with Safranin-O/fast green. Representative images of mouse joints are shown (n=8 mice per time point). B. Maximal histological scores across the femoral condyle. C. Maximal histological scores across the tibial plateau. *P<0.05, **P<0.01, ***P<0.001, n.s, no significant.